Health Technology

Acxiom CIO Janet Cinfio Named a Women in Tech Leader to Watch in 2024

Retrieved on: 
Thursday, April 4, 2024
Consulting, Data Management, Technology, Professional Services, Health, Health Technology, Other Technology, Data Analytics, Software, Artificial Intelligence, Other Professional Services, CIO, Inclusion, Organization, Mentorship, Woman, Bias, Georgetown University, Education, Female, Electronic Arts, IDEA, Architecture, Morale, Empowerment, STEM, BRG, Multimedia, Family, Workplace, Janet, Management

Acxiom , a global leader in customer intelligence, today proudly announced that Chief Information Officer (CIO) Janet Cinfio earned a spot on the Womentech Network's " 100 Women in Tech Leaders to Watch in 2024 ."

Key Points: 
  • Acxiom , a global leader in customer intelligence, today proudly announced that Chief Information Officer (CIO) Janet Cinfio earned a spot on the Womentech Network's " 100 Women in Tech Leaders to Watch in 2024 ."
  • View the full release here: https://www.businesswire.com/news/home/20240404573052/en/
    Acxiom CIO Janet Cinfio (Photo: Business Wire)
    As CIO at Acxiom, Janet is the pivotal force guiding the company's information technology (IT) strategy.
  • She has been instrumental in advancing Acxiom's technology capabilities, encompassing cutting-edge innovations in architecture, cloud platforms, enterprise applications, and cybersecurity.
  • Notably, during her tenure, Acxiom witnessed a 16% increase in the percentage of women occupying senior leadership positions and 47% more women in tech leadership roles within the company since 2021.

NanoString Products Drive Breakthrough Cancer Research at the 2024 American Association of Cancer Research (AACR) Conference

Retrieved on: 
Thursday, April 4, 2024
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Inflammation, Harvard Medical School, DSP, Development, Gene expression, Immunotherapy, IL-6, Triple-negative breast cancer, RNA, King's College London, Immunology, Tumor microenvironment, Cancer, University, NanoString Technologies, Senior, Biology, Abstract, Pancreatic cancer, Neoplasm, Research and development, Hospital, Cell, SMI, MD Anderson Cancer Center, Blind spot, Medical imaging

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas.

Key Points: 
  • NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas.
  • The conference will be held in San Diego, April 5-10, 2024.
  • NanoString and its customers will showcase 110 posters and highlight its products in three oral presentations focusing on unique biological insights generated with its platforms.
  • “NanoString customers are using the highest plex protein and RNA spatial biology panels commercially available on cancer patient samples, making fundamental discoveries and answering key questions about patient response to advanced cancer therapies utilized today.

Paragonix Technologies Announces Nationwide Commercial Availability of FDA-Cleared BAROguard™ Donor Lung Preservation System

Retrieved on: 
Thursday, April 4, 2024
FDA, Health Technology, Health, Medical Devices, Lung, Massachusetts General Hospital, International Society, Transplant, Patient, Duke University Hospital, Research, Standard of care, Lung transplantation, MD, Surgeon, MSC, UCSF Medical Center, Atmosphere, Hospital, UCLA, Heart, UCLA Health, Medical device

Paragonix Technologies, Inc. , a pioneer in organ transplant technologies and procurement services, announces the full commercial launch of its next-generation transport device, the BAROguard™ Donor Lung Preservation System .

Key Points: 
  • Paragonix Technologies, Inc. , a pioneer in organ transplant technologies and procurement services, announces the full commercial launch of its next-generation transport device, the BAROguard™ Donor Lung Preservation System .
  • First-of-its-kind, the novel BAROguard system combines clinically proven hypothermic preservation techniques alongside active airway management control to ensure that donor lungs maintain optimal conditions during transport for maximum protection.
  • Paragonix Technologies received FDA 510(k) clearance for the device in August 2023, and conducted its first-in-human case at Duke University Medical Center in November 2023.
  • “The commercial launch of BAROguard represents a significant breakthrough for the organ transplantation industry,” said Dr. Lisa Anderson, CEO and President of Paragonix Technologies.

Corti Set to Disrupt the Health Wearable Market with the First Real-time, Continuous Monitor for Cortisol and Melatonin Hormones, the Key Stress and Sleep Hormones

Retrieved on: 
Thursday, April 4, 2024
Wearables, Mobile Technology, Technology, Mental Health, Fitness & Nutrition, Health Technology, Other Health, Health, General Health, Consumer Electronics, Moses Austin, Benchmarking, Hormone, Exercise, Professor, Inflammation, Biomarker, Research, Sleep, Melatonin, University, Doctor of Philosophy, Life, Eye, Diet, Management, Publication, Skin, Cortisol, Ageing, Medical device

The wearable features its proprietary passive-sweat sensor technology that non-invasively rests on your skin, day and night, continuously measuring biomarker levels.

Key Points: 
  • The wearable features its proprietary passive-sweat sensor technology that non-invasively rests on your skin, day and night, continuously measuring biomarker levels.
  • Now, it provides users with unmatched real-time insights into their wellness, establishing a new benchmark for the continuous monitoring of these critical biomarkers.
  • Corti redefines health monitoring by offering continuous, real-time visibility into the body's key stress and sleep hormones, Cortisol and Melatonin, marking a first in the wearable market.
  • Moreover, we are actively working with partnering businesses to discover new applications, enhancing its integration into various health and wellness ecosystems.

Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre

Retrieved on: 
Thursday, April 4, 2024
Cardiology, Biotechnology, Pharmaceutical, General Health, Health, Artificial Intelligence, Health Technology, Technology, Cardiovascular disease, Entrepreneurship, Health equity, Partnership, Risk, COVID-19, Patient, AI, Death, CHD, Medicine, CDC, Moyamoya disease, Medicare, McKinsey & Company, Medical device

This collaboration aims to significantly expand access to Cardio Diagnostics' industry-leading, AI-enabled precision cardiovascular diagnostic tests.

Key Points: 
  • This collaboration aims to significantly expand access to Cardio Diagnostics' industry-leading, AI-enabled precision cardiovascular diagnostic tests.
  • By leveraging the rapidly growing telehealth market, Cardio Diagnostics in partnership with Navierre is poised to revolutionize the patient cardiovascular care journey through earlier detection, accessible specialty care, and personalized prevention.
  • "We are thrilled to partner with Navierre to make our industry-leading cardiovascular clinical tests more widely available to patients and clinicians nationwide," said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics.
  • Cardio Diagnostics and Navierre are dedicated to creating a future where no one is left behind in the fight against cardiovascular disease.

UbiSim Wins 2024 Cool Tool Award from EdTech Digest

Retrieved on: 
Thursday, April 4, 2024
Technology, General Health, Science, Nursing, Health, Health Technology, Other Science, Other Education, Research, Other Technology, Training, University, Software, Education, Internet, Hardware, Artificial Intelligence, RN, VR, Communication, Name, Hospital, Next Generation, Generator, MSN, Workforce, Multimedia, Virtual reality

com ), the world’s first immersive virtual reality (VR) training platform built specifically for nurses and nursing simulation by Labster, has been named the winner of the Cool Tool Award for VR/AR by EdTech Digest.

Key Points: 
  • com ), the world’s first immersive virtual reality (VR) training platform built specifically for nurses and nursing simulation by Labster, has been named the winner of the Cool Tool Award for VR/AR by EdTech Digest.
  • In addition to winning the virtual reality/augmented reality solution category, UbiSim was also named a finalist in the professional skills (workforce, upskilling) solution category of the EdTech Awards.
  • UbiSim has been named the winner of the "Cool Tool Award" for VR/AR by EdTech Digest.
  • To schedule a UbiSim demo and see how immersive virtual reality can support clinical judgment and communication skills in your simulation lab, visit www.ubisimvr.com/request-demo .

SHL Telemedicine: Invitation to Conference Call Presenting Annual Results 2023

Retrieved on: 
Friday, April 5, 2024
Health, Apps, Applications, Technology, Telemedicine, Virtual Medicine, Health Technology, Software, Telehealth, SIX Swiss Exchange, CFO

SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN; NASDAQ: SHLT) ("SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions, today announced that it will publish its results for 2023 on Wednesday, April 17, 2024 at 7 am CET.

Key Points: 
  • SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN; NASDAQ: SHLT) ("SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions, today announced that it will publish its results for 2023 on Wednesday, April 17, 2024 at 7 am CET.
  • The conference call for investors, journalists, and analysts to discuss the annual results 2023 will be hosted by Yariv Alroy, Chairman, Erez Nachtomy, CEO, and Amir Hai, CFO, and has been scheduled for the same day as following:
    The conference call can be accessed live via the below dial-in numbers:

U.S. FDA Renews DILIsym® Software Licenses for 7th Year

Retrieved on: 
Thursday, April 4, 2024
Data Management, Biotechnology, Technology, FDA, Health, Pharmaceutical, Health Technology, Research, Software, Artificial Intelligence, Science, Simulations Plus, Pharmacology, QST, Initiative, Partnership, Risk, QSP, SLP, Safety, Toxicology, Liver, Hepatotoxicity, Pharmaceutical industry

Dr. Paul B. Watkins, chair of the Scientific Advisory Board of the DILI-sim Initiative, said, “It is now known what properties to avoid to minimize liver toxicity in a new drug candidate -- but these same properties are often necessary to have therapeutic efficacy. By predicting safe dosing regimens of such drugs, DILIsym is now enabling successful development of important therapies that might otherwise be abandoned.”

Key Points: 
  • DILIsym is the industry gold standard for quantitative systems toxicology (QST) software designed for the prediction and investigation of drug-induced liver injury (DILI).
  • The one-year renewal provides the FDA with continued access to the DILIsym platform for authorized employees across all FDA divisions.
  • It also allows the FDA to evaluate the potential DILI risk across multiple populations, which supports informed decision-making regarding drug approvals.
  • Companies interested in a free trial version of the DILIsym software can request it here .

Velsera and Flywheel Team up to Support Multimodal Imaging Genomics Research

Retrieved on: 
Thursday, April 4, 2024
Other Health, General Health, Radiology, Pharmaceutical, Medical Devices, Technology, Hospitals, Artificial Intelligence, Genetics, Health Technology, Biotechnology, Health, Genomics, Algorithm, MRI, FHIR, Down syndrome, Environment, Investigation, Disease, Patient, Artificial intelligence, AI, PB, NIH, Ecosystem, Privacy, Government, Syndrome, Metadata, Medical imaging

Combining their capabilities, Velsera, Flywheel, and D3b were able to manage, harmonize, and analyze large datasets in a cloud-based platform.

Key Points: 
  • Combining their capabilities, Velsera, Flywheel, and D3b were able to manage, harmonize, and analyze large datasets in a cloud-based platform.
  • The Velsera team created interoperability standards that allow platforms to communicate with each other and make large-scale data access transparent to the user.
  • “Linking our Flywheel Core Platform with Velsera’s CAVATICA platform facilitates an unparalleled ability to perform advanced, multimodal data analysis in a cloud environment,” said Travis Richardson, Chief Strategist at Flywheel.
  • Using data from D3b, teams were able to analyze the combination of extracted imaging features on the Flywheel Core Platform.

Johnson & Johnson Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation

Retrieved on: 
Thursday, April 4, 2024
General Health, Health Technology, Health, Disclosure, JNJ, Letter, Johnson & Johnson, Pharmaceutical industry

Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to purchase up to 1 million shares of Johnson & Johnson common stock at a price of $151.23 per share in cash.

Key Points: 
  • Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to purchase up to 1 million shares of Johnson & Johnson common stock at a price of $151.23 per share in cash.
  • The offer is for approximately 0.04% of the shares of Johnson & Johnson common stock outstanding as of the April 3, 2024 offer date.
  • Johnson & Johnson is not associated in any way with TRC Capital Investment or its unsolicited mini-tender offer and recommends that shareholders do not tender their shares in response to TRC Capital Investment’s offer because the offer is at a price below the current market price for Johnson & Johnson’s shares and subject to numerous conditions.
  • Johnson & Johnson recommends that shareholders who have not responded to TRC Capital Investment’s offer take no action.